Poria acid inhibit the growth and metastasis of renal cell carcinoma by inhibiting the PI3K/akt/NF-κb signaling pathway. 2024

Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
Department of Pharmacy, Hebei Key Laboratory of Clinical Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China.

Poria acid (PAC) is a triterpene compound found in Poria cocos, a traditional Chinese medicine (TCM). The current study aims to explore the therapeutic effects and potential mechanisms of PAC on the migration and proliferation of human renal cell carcinoma (RCC) cells as well as tumor growth in animal model. Cell viability and proliferative capacity of normal renal cells and RCC cells were investigated by MTT assay. In addition, 786-O cells were divided into four groups and treated with different concentrations of PAC (0, 20, 40, and 60 μM) for 48 h. Cell scratch test and cell invasion assay were performed to evaluate the effects of PAC on the invasion and migration of RCC cells, respectively. The effects of PAC on apoptosis of RCC cells and expression levels of PI3K/Akt/NF-kB signaling pathway-related biomarkers were investigated using TUNEL staining and Western blotting methods, respectively. Effects of PAC on the inhibitory activity of RCC tumor in mice were evaluated in a 786-O CDX model. The study found that PAC inhibited the viability of RCC cells in a dose-dependent manner, as demonstrated by in vitro cell assays (p < 0.05). However, PAC showed no significant inhibitory effect on normal renal cells (p > 0.05). PAC also significantly inhibited the migration and invasion of RCC via EMT/MMP signaling pathways (p < 0.05). Immunofluorescence and immunoblotting results showed that PAC induced the apoptosis of RCC, which was accompanied by changes in the expression levels of apoptosis-related proteins (p < 0.05). Moreover, PAC significantly downregulated the PI3K/Akt/NF-kB signaling pathway in a concentration-dependent manner (p < 0.05). The effect of PAC on RCC apoptosis was dramatically reversed by 740Y-P (PI3K agonist) (p < 0.05) but significantly enhanced in the presence of LY294002 (PI3K inhibitor) (p < 0.05). The results of in vivo experiment also demonstrated that the antitumor activity of PAC was achieved by affecting the PI3K/Akt/NF-kB signaling pathway. PAC can effectively suppress the proliferation, invasion and migration of RCC cells, and exhibit anti-tumor effects in RCC model by inhibiting the PI3K/Akt/NF-kB signaling pathway.

UI MeSH Term Description Entries

Related Publications

Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
January 2024, Toxicology and applied pharmacology,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
September 2018, Oncology letters,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
December 2017, Oncotarget,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
August 2021, Journal of medicinal food,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
January 2024, Experimental and therapeutic medicine,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
January 2021, Frontiers in pharmacology,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
May 2024, Acta biochimica et biophysica Sinica,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
January 2023, Journal of agricultural and food chemistry,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
January 2023, Anti-cancer agents in medicinal chemistry,
Haotian Yang, and Yue Zhao, and Bingnan Ren, and Yin Wu, and Zhihong Qiu, and Yan Cheng, and Bo Qiu
April 2024, Inflammopharmacology,
Copied contents to your clipboard!